Literature DB >> 19450351

Diabetic retinopathy.

Efstratios Mendrinos1, Alexandros N Stangos, Constantin J Pournaras.   

Abstract

INTRODUCTION: Diabetic retinopathy is the most common cause of blindness in the UK, with older people and those with worse diabetic control, hypertension, and hyperlipidaemia being most at risk. Diabetic retinopathy can cause microaneurysms, haemorrhages, exudates, changes to blood vessels, and retinal thickening. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of treatments in people with diabetic retinopathy? What are the effects of treatments for vitreous haemorrhage? We searched: Medline, Embase, The Cochrane Library and other important databases up to November March 2007 (Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).
RESULTS: We found 29 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.
CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: peripheral retinal laser photocoagulation, focal and grid laser photocoagulation for maculopathy, corticosteroids for macular oedema, and vitrectomy for vitreous haemorrhage.

Entities:  

Mesh:

Year:  2007        PMID: 19450351      PMCID: PMC2943811     

Source DB:  PubMed          Journal:  BMJ Clin Evid        ISSN: 1462-3846


  44 in total

1.  TPA-assisted vitrectomy for proliferative diabetic retinopathy: results of a double-masked, multicenter trial.

Authors:  Y Le Mer; J F Korobelnik; C Morel; M Ullern; J P Berrod
Journal:  Retina       Date:  1999       Impact factor: 4.256

2.  Early vitrectomy for severe proliferative diabetic retinopathy in eyes with useful vision. Results of a randomized trial--Diabetic Retinopathy Vitrectomy Study Report 3. The Diabetic Retinopathy Vitrectomy Study Research Group.

Authors: 
Journal:  Ophthalmology       Date:  1988-10       Impact factor: 12.079

3.  Peripheral retinal ablation in the treatment of proliferative diabetic retinopathy: a three-year interim report of a randomised, controlled study using the argon laser.

Authors:  B L Hercules; I I Gayed; S B Lucas; J Jeacock
Journal:  Br J Ophthalmol       Date:  1977-09       Impact factor: 4.638

4.  Macular edema--an overlooked complication of diabetic retinopathy.

Authors:  A Patz; H Schatz; J W Berkow; A M Gittelsohn; U Ticho
Journal:  Trans Am Acad Ophthalmol Otolaryngol       Date:  1973 Jan-Feb

5.  Diabetic retinopathy. A further study of prognosis for vision.

Authors:  F I Caird; A F Burditt; G J Draper
Journal:  Diabetes       Date:  1968-03       Impact factor: 9.461

6.  Photocoagulation in diabetic retinopathy.

Authors:  A E Krill; D B Archer; F W Newell; M I Chishti
Journal:  Am J Ophthalmol       Date:  1971-08       Impact factor: 5.258

7.  Prognosis of proliferative retinopathy in juvenile diabetics.

Authors:  T Deckert; S E Simonsen; J E Poulsen
Journal:  Diabetes       Date:  1967-10       Impact factor: 9.461

8.  Light panretinal photocoagulation (LPRP) versus classic panretinal photocoagulation (CPRP) in proliferative diabetic retinopathy.

Authors:  F Bandello; R Brancato; U Menchini; G Virgili; P Lanzetta; E Ferrari; C Incorvaia
Journal:  Semin Ophthalmol       Date:  2001-03       Impact factor: 1.975

9.  Diabetic macular edema and argon laser photocoagulation: a prospective randomized study.

Authors:  G W Blankenship
Journal:  Ophthalmology       Date:  1979-01       Impact factor: 12.079

10.  Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group.

Authors: 
Journal:  Ophthalmology       Date:  1981-07       Impact factor: 12.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.